The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Therapy of human solid tumor xenografts with CD74-targeted milatuzumab-SN-38 immunoconjugates.
David M. Goldenberg
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics
Thomas M. Cardillo
Employment or Leadership Position - Immunomedics
Robert M. Sharkey
No relevant relationships to disclose
David V. Gold
No relevant relationships to disclose
Serengulam V. Govindan
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics (B)